When Biogen announced in March 2019 that their vaunted Alzheimer’s drug aducanumab failed two large late-studies, Rachael Neve wondered whether the field might finally move on. For 30 years, Alzheimer’s research had been dominated by a single theory: The amyloid hypothesis, or the idea that the devastating condition could be traced to sticky plaques that … Continue reading Whatever the FDA decides on aducanumab, Alzheimer’s research is finally, mostly, kind of moving beyond the amyloid hypothesis